NEUROONE MEDICAL TECHNOLOGIES Corp

Listed Company

NMTCCIK 0001500198NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Sep 30

Period

FY 2025

Revenue

$9.10M

Net Income

$-3.61M

Total Assets

$10.79M

Equity

$7.07M

Shares Out

8.70M

Op. Cash Flow

$-2.84M

NMTC$2.34−48.66% · past yearDBEQ Basic

Daily closing prices

Business

NeuroOne Medical Technologies is a medical-device company developing diagnostic, ablation, and deep brain stimulation technologies for neurological conditions including epilepsy, Parkinson's disease, and pain management. The company markets four FDA-cleared devices: Evo Cortical and Evo sEEG electrodes for temporary brain monitoring and stimulation, and OneRF Brain and OneRF TN ablation systems for radiofrequency lesion creation. Products in development include spinal cord stimulation systems, basivertebral nerve ablation, and drug-delivery electrodes with recording capability. Zimmer Biomet distributes the cleared products globally under an exclusive distribution agreement.

Summary from 10-K filed 2025-12-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Product revenue	9	3	2	171,169	178,146
Cost of product revenue	4	2	1	241,963	275,895
Product gross profit	5	1	456,517	−70,794	−97,749
Collaborations revenue	3	—	—	—	—
Selling, general and administrative	7	8	7	7	6
Research and development	5	5	7	5	4
Total operating expenses	12	13	14	12	10
Loss from operations	−4	−12	−12	−10	−10
Fair value change in warrant liability	784,670	−327,092	—	—	—
Financing costs	−334,063	−228,988	—	—	—
Other income, net	170,492	125,179	—	—	—
Loss before income taxes	−4	−12	−12	−10	—
Provision for income taxes	—	—	—	—	271,122
Net loss	−4	−12	−12	−10	−10
Basic (in Dollars per share)	−0.09	−0.46	−0.65	−0.63	−0.93
Diluted (in Dollars per share)	−0.09	−0.46	−0.65	−0.63	−0.93
Basic (in Shares)	40	27	18	16	11
Diluted (in Shares)	40	27	18	16	11

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Cash and cash equivalents	7	1	5	8	7
Accounts receivable	1	176,636	—	33,237	48,336
Inventory	2	3	2	704,538	98,287
Deferred offering costs	22,920	142,633	—	—	—
Prepaid expenses	141,372	216,461	263,746	296,649	244,043
Total current assets	10	5	7	12	7
Intangible assets, net	44,946	67,262	89,577	111,892	134,207
Right-of-use asset	255,195	254,910	169,059	181,355	288,948
Property and equipment, net	259,222	416,843	525,753	353,599	223,329
Total assets	11	5	8	13	8
Accounts payable	1	1	685,104	927,662	528,829
Accrued expenses and other liabilities	1	1	—	—	—
Total current liabilities	2	2	2	3	1
Warrant liability	1	2	—	—	—
Operating lease liability, long term	143,148	194,392	55,284	119,556	202,895
Total liabilities	4	5	2	3	1
Commitments and contingencies (Note 4)	—	—	—	—	—
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding.	—	—	—	—	—
Common stock, $0.001 par value; 100,000,000 shares authorized; 50,006,464 and 30,816,499 shares issued and outstanding as of September 30, 2025 and 2024, respectively.	50,006	30,816	23,929	16,217	12,010
Additional paidin capital	86	76	69	60	47
Accumulated deficit	−79	−75	−63	−51	−41
Total stockholders equity	7	822,013	6	10	7
Total liabilities and stockholders equity	11	5	8	13	8

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Amortization and depreciation	261,679	246,791	199,266	—	—
Amortization of deferred issuance costs	192,647	101,329	—	—	—
Stock-based compensation	1	1	1	947,212	—
Debt and equity facility costs reclassified to financing activities	141,416	127,659	—	—	—
Non-cash lease expense	111,613	113,534	109,832	—	—
Valuation adjustments for excess or obsolete inventory	10,000	—	—	—	—
Accounts receivable	−1	−176,636	33,237	15,099	−48,336
Inventory	398,348	−908,467	−1	−606,251	−98,287
Prepaid expenses	75,089	47,285	32,903	—	—
Accounts payable	239,983	66,993	−247,189	515,438	−350,313
Accrued expenses, operating lease and other liabilities	−54,442	16,214	−1	1	—
Net cash used in operating activities	−3	−11	−13	−8	−9
Purchases of property and equipment	−81,742	−120,197	−384,117	−275,226	−67,079
Net cash used in investing activities	−81,742	−120,197	3	−3	−67,079
Proceeds from issuance of common stock in connection with private placement	—	836,777	—	—	—
Proceeds from issuance of warrants in connection with private placement	—	2	—	—	—
Proceeds from issuance of common stock attributed to non-private placement equity offerings	10	5	—	—	—
Issuance costs attributed to common stock and warrants issued in private placement	−185,903	−1,320	—	—	—
Issuance costs related to non-private placement equity offerings	−1	−236,597	—	—	—
Deferred issuance costs in connection with at-the-market offering program	—	−20,000	−234,725	—	—
Deferred issuance costs in connection with debt facility	−297,942	−75,000	—	—	—
Exercise of warrants	69,750	—	—	—	275,000
Share repurchases for the payment of employee taxes	−124,617	−81,403	−119,419	—	—
Net cash provided by financing activities	8	7	7	12	12
Net increase (decrease) in cash and cash equivalents	5	−4	−3	1	3
Modification of right-of-use asset and associated lease liability	111,898	199,385	97,536	—	—
Non-cash warrants issued in connection with debt facility	—	53,124	—	—	—
Unpaid issuance costs in connection with private placement	—	185,903	—	—	—
Unpaid deferred issuance costs	22,920	95,837	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is NEUROONE MEDICAL TECHNOLOGIES Corp's CIK number?

NEUROONE MEDICAL TECHNOLOGIES Corp's SEC CIK number is 0001500198 (1500198). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find NEUROONE MEDICAL TECHNOLOGIES Corp's SEC filings?

All of NEUROONE MEDICAL TECHNOLOGIES Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did NEUROONE MEDICAL TECHNOLOGIES Corp last report earnings?

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-054744). This is NEUROONE MEDICAL TECHNOLOGIES Corp's most recent earnings filing of record — not a forecast of its next earnings date.

What is NEUROONE MEDICAL TECHNOLOGIES Corp's most recent earnings 8-K?

NEUROONE MEDICAL TECHNOLOGIES Corp's latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001213900-26-054744. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View NEUROONE MEDICAL TECHNOLOGIES Corp's latest earnings 8-K →
Look up any company's CIK number →